文献速递肿瘤 PET/CT神经核医学

18F-PSMA-1007 PET/CT在检测肾细胞癌脑转移中的增量价值

Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
PubMed 文献 · Clin Nucl Med · 2022-04-27

本文报告一名44岁已知肾细胞癌男性在根治性肾切除术后再分期中接受18F-PSMA与18F-FDG PET/CT,发现小脑单发边界清晰病灶PSMA表达显著而FDG摄取不确定,脑MRI证实为匹配的小脑转移灶。作者认为转移性肾细胞癌中的18F-PSMA表达为未来诊疗一体化应用提供了前瞻性指导。

要点

  • 44岁男性肾细胞癌根治性肾切除术后再分期,行18F-PSMA与18F-FDG PET/CT。
  • 小脑单发边界清晰病灶PSMA表达显著、FDG摄取不确定,脑MRI证实为匹配转移灶。
  • 作者认为转移性肾细胞癌的18F-PSMA表达为未来诊疗一体化应用提供前瞻性指导。

核心结论

  • 作者认为转移性肾细胞癌中的18F-PSMA表达为未来诊疗一体化应用提供了前瞻性指导。

研究设计与样本

  • 本文为病例报告,报告一名44岁已知肾细胞癌男性在根治性肾切除术后再分期中接受18F-PSMA与18F-FDG PET/CT。

主要发现

  • 18F-PSMA PET/CT显示小脑单发边界清晰病灶PSMA表达显著,同病灶18F-FDG摄取不确定。
  • 脑MRI证实存在与PET所见匹配的小脑转移灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-PSMA PET/CT is an emerging standard of care in staging prostate cancer, evaluating biochemical recurrence and response to therapy. Despite the nomenclature, PSMA expression is also documented at the tumor-associated neovasculature of other malignant solid tumors including renal cell carcinoma. We report a case of 44-year-old man known to have renal cell carcinoma who underwent 18F-PSMA and 18F-FDG PET/CT for restaging after radical nephrectomy. A well-defined solitary cerebellar lesion with marked PSMA expression and equivocal FDG uptake was noted. MRI brain confirmed a matching cerebellar metastatic lesion. 18F-PSMA expression in the metastatic RCC raises a prospective guide to futuristic theragnostic uses.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sadeq A, Usmani S, Esmail AA, et al. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain. Clin Nucl Med. 2022. PMID: 35675136. doi:10.1097/RLU.0000000000004162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。